Fighting sedentary time in young cancer patients: a digital intervention put to the test

NCT ID NCT07742891

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether a 10-week mobile health program, called ReSeT2, can reduce the time adolescents and young adults with acute lymphoblastic leukemia (ALL) spend sitting during maintenance therapy. Participants aged 13-22 will be randomly assigned to either the intervention—which includes a Fitbit with inactivity prompts, home activity equipment, coaching, and peer support—or usual care. The study measures changes in sedentary time and explores effects on cardiometabolic health and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A 10-week mobile health intervention combining a Fitbit with inactivity prompts, home activity equipment, goal-based incentives, coaching, and peer support
What this could lead to
If effective, this approach could offer a practical way to reduce sedentary time and improve cardiometabolic health in young leukemia patients during maintenance therapy.
What could go wrong
This is a small pilot study, so results may not be conclusive. The intervention's success depends on participant engagement, and it may not lead to lasting changes or generalizable outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Sedentary Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.